Verily Life Sciences (formerly Google Life Sciences) is an Alphabet company dedicated to integrating advanced technology and healthcare to improve patient outcomes across a range of chronic diseases. Founded in 2015 as a subsidiary of Google (now Alphabet), Verily leverages expertise in machine learning, hardware engineering, and data science to develop innovative solutions for disease monitoring, diagnosis, and management.
The company's name "Verily" reflects its commitment to truth and certainty in medical evidence, emphasizing its data-driven approach to healthcare. Based in South San Francisco, California, Verily operates as an independent Alphabet company with a mission to make the world's health data useful so that people enjoy healthier lives[verily].
Verily's work in neurodegenerative disease focuses on Parkinson's disease and Alzheimer's disease monitoring, leveraging its expertise in wearable sensors, software platforms, and artificial intelligence to improve clinical care and research.
| Attribute |
Value |
| Headquarters |
South San Francisco, California, USA |
| Founded |
2015 (as Google Life Sciences) |
| Parent |
Alphabet Inc. |
| Focus |
Digital health, disease monitoring, AI diagnostics |
| Employees |
~500+ (as of 2024) |
Verily benefits from Alphabet's broader ecosystem of artificial intelligence and machine learning capabilities, including access to Google Brain, DeepMind, and other Alphabet AI research initiatives.
Verily has developed proprietary wearable sensors for continuous physiological monitoring:
- Movement monitoring: Accelerometer-based devices for detecting tremor, bradykinesia, and gait disturbances in PD patients
- Sleep tracking: Bed-based sensors for monitoring sleep architecture and detecting rapid eye movement (REM) sleep behavior disorder, a prodromal PD marker
- Heart rate variability: Continuous ECG monitoring for autonomic function assessment
- Activity patterns: Real-time tracking of daily activities and functional status
The company's sensor platform has been validated in multiple clinical studies, demonstrating agreement with clinician assessments and standard outcome measures[espay2020].
Verily Study Hub is a comprehensive platform for managing clinical research studies:
- Patient recruitment: Digital screening and enrollment tools
- Data collection: Integration with electronic health records and patient-reported outcomes
- Remote monitoring: Virtual visits and at-home sample collection
- Analytics: Real-time data visualization and analysis dashboards
Onduo is a virtual care platform developed in partnership with Medtronic and other healthcare providers. While primarily focused on metabolic diseases, Onduo has expanded to include movement disorder monitoring capabilities:
- Virtual consultations: Neurologist access through telemedicine
- Medication management: Digital tools for tracking and optimizing therapy
- Symptom tracking: Patient-reported outcome collection
- Care coordination: Integration with primary care and specialist providers
Verily applies machine learning and deep learning approaches to healthcare data:
- Disease detection: Algorithms for identifying early signs of neurological disease from sensor data
- Outcome prediction: Models for predicting disease progression and treatment response
- Clinical decision support: Tools to assist clinicians in diagnosis and treatment selection
- Biomarker discovery: Automated analysis of imaging, biosensor, and genetic data
The company's AI capabilities are built on Google infrastructure, enabling processing of large datasets and rapid algorithm development[taylor2020].
Verily's primary focus in PD is the development of digital biomarkers—objective, quantifiable physiological measures collected via digital devices that correlate with clinical endpoints:
- Tremor: Detection and characterization of resting tremor using wrist-worn accelerometers
- Bradykinesia: Quantitative assessment of movement speed and amplitude
- Gait: Analysis of stride length, cadence, and variability during walking
- Dyskinesia: Differentiation from true PD symptoms using motion patterns
- Sleep: Detection of REM sleep behavior disorder and other sleep disturbances
- Cognitive function: Digital assessments of processing speed, attention, and memory
- Mood: Detection of depression and anxiety through activity patterns and self-report
Verily has partnered with major academic medical centers to validate its monitoring technologies:
- NIH-funded studies: Remote monitoring of motor symptoms in PD patients
- Clinical trials: Objective outcome measures for drug development
- Observational studies: Natural history data collection
- Care optimization: Real-world evidence generation
Verily collaborates with leading institutions:
- University of Rochester: PD clinical research
- Massachusetts General Hospital: Movement disorders program
- Parkinson's Foundation: Patient engagement and advocacy
- Michael J. Fox Foundation: Research initiatives and data sharing
Verily is applying its digital health expertise to Alzheimer's disease:
- Cognitive assessments: Digital versions of standard cognitive tests (MMSE, MoCA)
- Activity monitoring: Detection of functional decline through daily activity patterns
- Sleep analysis: Correlation of sleep architecture with cognitive status
- Speech analysis: Machine learning on voice recordings for early detection
The company provides infrastructure for AD research:
- Study management: Tools for recruitment, data collection, and monitoring
- Sensor integration: Wearable and home-based monitoring devices
- Data analysis: Machine learning pipelines for biomarker discovery
¶ Products and Services
The Verily Study Hub provides end-to-end support for clinical research:
| Feature |
Description |
| Patient recruitment |
Digital enrollment and screening |
| Data collection |
EHR integration, patient portals |
| Remote monitoring |
Wearables, at-home testing |
| Analytics |
Real-time dashboards, ML tools |
| Compliance |
Regulatory adherence, security |
Onduo is a virtual care platform:
- Chronic disease management: Diabetes, hypertension, and other conditions
- Movement disorders: PD monitoring and care coordination
- Personalized coaching: Health coaching and medication reminders
- Provider network: Access to specialists via telemedicine
Verily offers customized research solutions:
- Study design consultation
- Sensor deployment and management
- Data infrastructure and analytics
- Regulatory support
¶ Competitive Landscape
Verily operates in the digital health and digital therapeutics space:
| Company |
Product |
Focus |
Status |
| Roche |
mySugr |
Diabetes management |
Commercial |
| Apple |
HealthKit |
Wearable integration |
Commercial |
| Livongo |
Health |
Chronic disease |
Acquired by Teladoc |
| Biogen |
CogniFit |
Cognitive training |
Commercial |
| Verily |
Study Hub |
Research platform |
Commercial |
Verily differentiates through:
- Alphabet AI/ML capabilities
- Hardware engineering expertise
- Scale and resources of Alphabet
- Integration across health data sources
- Mayo Clinic: PD research and clinical validation
- Cleveland Clinic: Digital health implementation
- Kaiser Permanente: Real-world evidence generation
- Pfizer: Alzheimer's and Parkinson's research collaboration
- Novartis: Digital health solutions for neurological disorders
- Biogen: Clinical trial technology
- Medtronic: Onduo platform partnership
- Dexcom: Continuous glucose monitoring integration
- Abbott: Sensor integration
- Stanford Medicine: Research collaboration
- Johns Hopkins: Digital health research
- University of California: Multiple partnerships
-
Parkinson's disease
- Digital biomarkers for motor symptoms
- Wearable monitoring devices
- Clinical trial endpoints
- Patient management tools
-
Alzheimer's disease
- Early detection algorithms
- Cognitive assessment platforms
- Caregiver support tools
- Research infrastructure
- Cardiometabolic disease: Diabetes, hypertension, heart failure
- Mental health: Depression, anxiety screening
- Respiratory: Asthma, COPD management
- Oncology: Remote monitoring during treatment
Verily's strategic priorities include:
- Regulatory clearance: FDA clearance for digital biomarkers in PD
- Clinical adoption: Integration into standard of care
- Expansion: Broader neurodegenerative disease focus
- Partnerships: Increased pharma and healthcare system collaborations
- International: Global market expansion